Alexion purchased undisclosed patents and assets from Orphatec related to Orphatec's cyclic pyranopterin monophosphate (cPMP) replacement therapy to treat MoCD Type A

Orphatec Pharmaceuticals GmbH

Germany / Private Biopharma

Seller

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Alexion Pharmaceuticals Inc.

U.S. / Mid-Cap Biopharma ($1-$50 billion)

Buyer

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced